7.47 USD
-0.1 (-1.32%)
At close: Jan 30, 2026
7.35 USD
-0.12 (-1.61%)
After Hours: 1/30/2026, 8:00:01 PM
ARCT gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ARCT as it has an excellent financial health rating, but there are worries on the profitability. ARCT is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- ARCT had negative earnings in the past year.
- In the past year ARCT has reported a negative cash flow from operations.
- In the past 5 years ARCT reported 4 times negative net income.
- ARCT had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- ARCT's Return On Assets of -23.63% is fine compared to the rest of the industry. ARCT outperforms 72.76% of its industry peers.
- ARCT has a better Return On Equity (-29.71%) than 76.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.63% | ||
| ROE | -29.71% | ||
| ROIC | N/A |
ROA(3y)-9.46%
ROA(5y)-19.07%
ROE(3y)-13.61%
ROE(5y)-29.65%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ARCT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- ARCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for ARCT has been increased compared to 1 year ago.
- The number of shares outstanding for ARCT has been increased compared to 5 years ago.
- ARCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- Based on the Altman-Z score of 0.15, we must say that ARCT is in the distress zone and has some risk of bankruptcy.
- The Altman-Z score of ARCT (0.15) is better than 61.71% of its industry peers.
- ARCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.15 |
ROIC/WACCN/A
WACC8.9%
2.3 Liquidity
- A Current Ratio of 7.86 indicates that ARCT has no problem at all paying its short term obligations.
- The Current ratio of ARCT (7.86) is better than 73.71% of its industry peers.
- A Quick Ratio of 7.86 indicates that ARCT has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 7.86, ARCT is in the better half of the industry, outperforming 73.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.86 | ||
| Quick Ratio | 7.86 |
3. Growth
3.1 Past
- ARCT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -10.81%.
- Looking at the last year, ARCT shows a very negative growth in Revenue. The Revenue has decreased by -39.15% in the last year.
- Measured over the past years, ARCT shows a very strong growth in Revenue. The Revenue has been growing by 48.91% on average per year.
EPS 1Y (TTM)-10.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-88.46%
Revenue 1Y (TTM)-39.15%
Revenue growth 3Y130.73%
Revenue growth 5Y48.91%
Sales Q2Q%-58.84%
3.2 Future
- Based on estimates for the next years, ARCT will show a very strong growth in Earnings Per Share. The EPS will grow by 31.33% on average per year.
- Based on estimates for the next years, ARCT will show a very strong growth in Revenue. The Revenue will grow by 24.00% on average per year.
EPS Next Y31.64%
EPS Next 2Y-2.96%
EPS Next 3Y16.19%
EPS Next 5Y31.33%
Revenue Next Year-47.91%
Revenue Next 2Y-31.94%
Revenue Next 3Y-0.67%
Revenue Next 5Y24%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- ARCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year ARCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as ARCT's earnings are expected to grow with 16.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.96%
EPS Next 3Y16.19%
5. Dividend
5.1 Amount
- ARCT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ARCTURUS THERAPEUTICS HOLDIN / ARCT FAQ
Can you provide the ChartMill fundamental rating for ARCTURUS THERAPEUTICS HOLDIN?
ChartMill assigns a fundamental rating of 4 / 10 to ARCT.
What is the valuation status for ARCT stock?
ChartMill assigns a valuation rating of 0 / 10 to ARCTURUS THERAPEUTICS HOLDIN (ARCT). This can be considered as Overvalued.
What is the profitability of ARCT stock?
ARCTURUS THERAPEUTICS HOLDIN (ARCT) has a profitability rating of 1 / 10.